RAS GTPase family inhibitor
1 abstract
Abstract
Symptomatic adverse events in lung cancer clinical trials included in US drug labels from 2015 to 2021 to inform patient-reported outcomes.Org: Oncology Center of Excellence, U.S. Food and Drug Administration, ORISE Fellow, Center for Drug Evaluation and Research, Office of Oncologic Diseases,